Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
Minimalist representation of a PD-L1 antibody

Jun 5, 2026

AI collaboration to advance digital pathology

Leica Biosystems, Indica Labs, and Lunit have announced a strategic partnership aimed at enhancing digital pathology through AI-powered image analysis algorithms, particularly for PD-L1 and other immunohistochemistry biomarkers.This collaboration builds on an existing relationship between Leica Biosystems and Indica Labs, now integrating Lunit’s advanced AI technology into a comprehensive digital pathology ecosystem. The initial product from this partnership is the Lunit SCOPE algorithm, designe
A minimalist representation of a stethoscope and a speech bubble symbolizing AI in healthcare.

Jun 5, 2026

ChatGPT tops physicians’ AI tools, raising pharma visibility stakes

Recent data highlights the significant role of AI tools in clinical practice, particularly the prominence of ChatGPT among physicians. A survey conducted in March 2026 revealed that a staggering 92% of doctors across various specialties are utilizing generative AI, including both general platforms like ChatGPT and specialized healthcare tools.This high adoption rate is consistent across the medical field, with no specialty reporting usage below 85%. Looking ahead, 85% of physicians anticipate in
A stock certificate and financial report on an office desk

Jun 5, 2026

Redwood AI’s Strategic Pivot Fails to Impress as Volatility Surges Past 130%

Redwood AI is experiencing significant stock volatility despite securing partnerships and government funding, indicating investor skepticism.The Canadian AI company Redwood AI has seen its stock price decline by 14% over the past week, closing at C$3.85 after a 3.75% drop on Thursday. This downturn occurs even as the firm has made strides in securing partnerships, government grants, and plans for a U.S. market entry. The company's volatility is notable, with a 30-day annualized figure exceeding
A diagnostic test kit in a dimly lit lab

Jun 4, 2026

A Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus

Agilent Technologies (A) is gaining attention following recent developments, including FDA approval for its PD-L1 diagnostic, a new AI partnership with OpenAI and Boston Consulting Group, and better-than-expected quarterly earnings with updated guidance.The company's stock has seen significant growth, with a 17.73% increase over the past month and a 20.25% rise over the last three months. Over the past year, shareholders have enjoyed a total return of 22.44%, indicating a positive trend in inves
A stethoscope on a medical chart in an office setting

Jun 4, 2026

Oscar Health CTO Shift Tests AI Execution And Investor Confidence

The recent transition of Mario Schlosser, co-founder and former CTO of Oscar Health, to an advisory role focused on AI and digital health has sparked investor concerns regarding the company's technological direction and leadership continuity.Schlosser will remain on the Board, ensuring his influence on Oscar's AI initiatives despite stepping back from daily operations. This leadership change comes at a time when Oscar's stock has experienced fluctuations, closing recently at $20.50. While the st
A robotic arm working on a circuit board in a workshop

Jun 4, 2026

10 Top Tech Companies in Munich

Munich stands out as a significant technology hub in Europe, showcasing a diverse range of sectors including AI, robotics, and medtech. Major players like BMW Group and Celonis contribute to the city's dynamic tech landscape, leveraging its rich engineering talent.The city is recognized for its expertise in areas such as autonomous mobility and data science, with a workforce heavily composed of systems engineers. Notable academic institutions, including the Technical University of Munich and Lud
A pill bottle and prescription pad on a pharmacy counter in low light.

Jun 4, 2026

Veeva Rides AI Wave As Pharma Cloud Story Accelerates

Veeva Systems Inc. is experiencing significant growth, driven by robust financial results and advancements in AI technology. In its recent quarterly report, Veeva announced a 16% year-on-year revenue increase, reaching $882.9 million, and a 13% rise in adjusted operating income to $395.4 million. These figures surpassed analyst expectations, prompting the company to raise its fiscal 2027 guidance across all major metrics. Analysts from BTIG and Needham have affirmed their Buy ratings, highlighti
A minimalist representation of a data chart symbolizing growth in life sciences investment.

Jun 4, 2026

From data to deals: AI’s impact on life sciences investing

At a recent symposium in Paris, experts discussed the transformative role of AI in life sciences investing, highlighting its rapid adoption and the challenges of regulatory frameworks keeping pace with technological advancements.The panel noted a significant change in sentiment compared to discussions held a year prior, with approximately 40% of attendees now viewing AI as integrated within their organizations. This shift underscores the urgency in addressing operational pressures faced by healt
A syringe filled with medication on a lab bench, with shelves of medical supplies in the background.

Jun 4, 2026

Sorcero CEO Dipanwita Das Among Only 3 Founders in Life Sciences AI Recognized on 2026 100 Women in AI

Dipanwita Das, CEO of Sorcero, has been honored as one of only three female founders in life sciences AI included in the 2026 100 Women in AI list. This recognition highlights Das's significant contributions to the field, placing her alongside leaders from major AI companies like OpenAI and Google. Sorcero, under her leadership, has developed an AI platform that addresses critical challenges in healthcare by enhancing the delivery of therapies to patients. The platform boasts impressive metrics,
A minimalist illustration of a lung and a clinical trial document on a solid background.

Jun 4, 2026

Massive Bio, Optellum Partner on Early Detection, Clinical Trial Access for Lung Cancer

Massive Bio and Optellum have joined forces to enhance early detection and clinical trial access for patients with non-small cell lung cancer (NSCLC), addressing a critical gap in cancer care.This partnership aims to bridge the disconnect between high-risk patients identified through routine imaging and their enrollment in clinical trials. Despite lung cancer being the leading cause of cancer-related deaths globally, many high-risk patients never participate in trials, which could significantly
A minimalist illustration of a pill and a medical cross.

Jun 4, 2026

How FDA Priority Review for First-in-Class LGMD Drug BBP-418 Could Impact BridgeBio Pharma (BBIO) Investors

BridgeBio Pharma has received FDA Priority Review for its New Drug Application for BBP-418, a potential treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), with a target decision date set for November 27, 2026. This marks a significant milestone as BBP-418 could become the first approved therapy for this condition, potentially earning BridgeBio a Priority Review Voucher and enhancing its prospects in the rare disease sector.This Priority Review introduces a pivotal regulatory ca
Silhouette of ginseng and mortar and pestle representing Traditional Chinese Medicine

Jun 4, 2026

AI-Powered TCM Leader: Yineng Pharma Named to Top 100 Innovative Medicine List

Yineng Pharma has achieved a significant milestone by being named to the "Top 100 Innovative Medicine and Biological Products" list at the Future Healthcare 100 Conference held in Shanghai. This recognition underscores the company's advancements in AI-powered Traditional Chinese Medicine (TCM) research and development, positioning it as a leader in the digitization of TCM.The Future Healthcare 100 Conference is a prominent event in China's health sector, attracting over 5,000 professionals, incl